CLINICAL TRIALS PROFILE FOR HYDROXYCHLOROQUINE SULFATE

All Clinical Trials for HYDROXYCHLOROQUINE SULFATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00946790 ↗	To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets	Completed	Sandoz	Phase 1	1993-07-01	To demonstrate the relative bioavailability of hydroxychloroquine sulfate, 200 mg tablets.
NCT01551069 ↗	Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion	Completed	Sanofi	Phase 3	2012-03-01	Primary Objective: - To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active skin manifestation (CLASI [Cutaneous Lupus Erythematosus Disease Area and Severity Index] activity score is ≥4) concomitant treatment with or without corticosteroid. Secondary Objectives: - To evaluate the efficacy on skin manifestation and the safety of 16 weeks treatment of once daily regiment of HCQ versus placebo as the reference group in patients with CLE and SLE with active skin manifestation (CLASI activity score is ≥4) concomitant treatment with or without corticosteroid. - To investigate the safety of 16 weeks treatment of once daily regiment of HCQ in patients with CLE and SLE with active skin manifestation concomitant treatment with or without corticosteroid. - To investigate the safety and efficacy of 52 weeks long-term treatment of once daily regimen of HCQ in patients with CLE and SLE - To investigate the influence of the dose reduction of corticosteroid on CLE and SLE patients treated with HCQ concomitant with corticosteroid - To investigate efficacy of once daily regimen of HCQ on systemic symptoms, musculoskeletal symptoms and immunological parameters in SLE patients.
NCT02351752 ↗	Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study	Completed	LLiu	Phase 4	2015-01-01	IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation. Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and showed the potential effect of treatment of patients with IgA nephropathy. The investigators study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.
NCT02615938 ↗	Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)	Suspended	Matthias Griese	Phase 2	2015-04-01	This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
NCT02765594 ↗	Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy	Unknown status	Peking Union Medical College Hospital	Phase 4	2016-06-01	Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and cytokines interleukin-6 (IL-6), and interferon-alpha (IFN-a) and tumor necrosis factor-alpha (TNF-α), play an important role in the aberrant mucosal response. Hydroxychloroquine is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting plasmacytoid dendritic cells, reduced production of inflammatory cytokines including interferon alpha, IL-6 and TNF alpha. Recent studies showed hydroxychloroquine had a benefit for renal remission and could retard the onset of renal damage in patients with lupus nephritis. hydroxychloroquine may have the potential effect in IgA nephropathy, alleviated the proteinuria and had the renal protect effect. This will be a single center, prospective, randomized, controlled study to assess the utility of hydroxychloroquine in IgAN patients.
NCT02942381 ↗	A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy	Completed	Peking University First Hospital	Phase 2	2016-09-13	The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.

Clinical Trial Conditions for HYDROXYCHLOROQUINE SULFATE

Condition Name

Condition Name for HYDROXYCHLOROQUINE SULFATE
Intervention	Trials
COVID-19	13
Covid19	4
SARS-CoV-2	3
Hydroxychloroquine	3

Condition MeSH

Condition MeSH for HYDROXYCHLOROQUINE SULFATE
Intervention	Trials
COVID-19	29
Coronavirus Infections	9
Severe Acute Respiratory Syndrome	7
Infection	5

Clinical Trial Locations for HYDROXYCHLOROQUINE SULFATE

Trials by Country

Trials by Country for HYDROXYCHLOROQUINE SULFATE
Location	Trials
United States	29
China	8
Germany	8
Brazil	3
Thailand	3

Trials by US State

Trials by US State for HYDROXYCHLOROQUINE SULFATE
Location	Trials
New York	4
New Jersey	3
Massachusetts	3
Washington	2
Louisiana	2

Clinical Trial Progress for HYDROXYCHLOROQUINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for HYDROXYCHLOROQUINE SULFATE
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	6

Clinical Trial Status

Clinical Trial Status for HYDROXYCHLOROQUINE SULFATE
Clinical Trial Phase	Trials
Completed	13
Recruiting	13
Active, not recruiting	5

Clinical Trial Sponsors for HYDROXYCHLOROQUINE SULFATE

Sponsor Name

Sponsor Name for HYDROXYCHLOROQUINE SULFATE
Sponsor	Trials
Rutgers, The State University of New Jersey	3
University of Washington	2
PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA	2

Sponsor Type

Sponsor Type for HYDROXYCHLOROQUINE SULFATE
Sponsor	Trials
Other	99
Industry	10
NIH	1

HYDROXYCHLOROQUINE SULFATE Market Analysis and Financial Projection

Last updated: April 27, 2026

Hydroxychloroquine Sulfate: Clinical Trial Status, Market Readout, and Forward Projections

What is the clinical-trial status for hydroxychloroquine sulfate?

Hydroxychloroquine sulfate is a repurposed, off-patent small molecule across most markets, and its clinical footprint has shifted from early COVID-19-era efficacy trials toward survivorship follow-up and low-frequency protocol work. Trial activity is concentrated in late-stage observational studies, endpoint-adjudication work, and post-exposure cohorts rather than new registrational programs.

COVID-era interventional trials: what outcomes drove the current landscape?

The global trial record led to broad guideline downgrades based on lack of consistent benefit and safety concerns at relevant exposures.

• The World Health Organization (WHO) updated guidance away from hydroxychloroquine for COVID-19, based on evidence from randomized trials and growing safety signals. (WHO, 2020) [1]
• The US NIH COVID-19 Treatment Guidelines moved hydroxychloroquine to a negative or “not recommended” position, reflecting trial evidence and risk-benefit assessments. (NIH, 2020) [2]
• Large randomized evidence materially shaped these decisions; the RECOVERY platform reported no clinical benefit for hospitalized patients. (RECOVERY Collaborative Group, 2020) [3]

These determinations curtailed late-stage interventional expansion and redirected clinical effort toward other candidates and combinations.

Trial activity today: typical pattern

Across registries and publications, hydroxychloroquine-related study sets now cluster into:

• observational cohorts for specific patient subtypes (autoimmune comorbidities, chronic use, comorbidity stratification)
• safety and pharmacovigilance analyses (long-term retinal and cardiometabolic monitoring where relevant)
• regional “post-guideline” utilization studies rather than placebo-controlled confirmatory trials

Because hydroxychloroquine sulfate is widely used for established indications, the clinical trial question has effectively become “where is it still being tested and why,” not “is it a new registration program.”

---

What is the market reality for hydroxychloroquine sulfate?

Hydroxychloroquine sulfate is a mature product with entrenched supply chains, multiple generics, and low pricing power. Market dynamics in the post-COVID period are driven by:

• guideline-driven demand changes for COVID-era use
• stable baseline autoimmune demand
• payer scrutiny and generic competition
• substitution into alternative therapies where applicable

Demand drivers and headwinds

Drivers

• Long-established use in autoimmune disease settings (where it remains part of standard therapeutic frameworks in many geographies)
• Low-cost generic availability supporting volume stability in cost-sensitive markets

Headwinds

• Residual stigma and guideline reversals following COVID-19 efficacy outcomes
• Regulatory and payer restrictions on off-label infectious-disease use in many jurisdictions
• Safety-driven monitoring burden where prescribing continues for unapproved uses

Pricing and competition structure

Hydroxychloroquine sulfate is typically priced at generic levels. The competitive set is characterized by:

• multiple ANDA/authorized generic products
• localized tendering in hospital systems
• substitution at pharmacy and formulary levels

This structure compresses margins and reduces the ability to sustain high incremental R&D-led price premiums.

---

How should investors and operators project volume and revenue forward?

Projection framework (directional, because the product is off-patent)

For a mature, genericized small molecule, projection must be framed as: 1) baseline autoimmune volume stability (less volatile) 2) off-label infectious use contribution (volatile, post-guideline erosion) 3) safety and regulatory constraints (tail-risk to utilization, not to manufacturing scale)

Base-case projection (2026 to 2029)

Under a base-case scenario consistent with guideline inertia and generic market structure:

• Autoimmune-driven demand remains the largest share of utilization with gradual growth aligned to population trends and disease prevalence.
• Infectious disease use remains a small share and does not recover to COVID-era peaks due to guideline positions and clinician preference.
• Revenue growth is limited by pricing compression in generics and by substitution dynamics.

Directional expectation: low single-digit global revenue CAGR with flat-to-slightly declining ex-COVID volume mix, assuming no major re-labeling or new evidence changes practice.

Downside projection

Downside occurs if:

• new safety signals intensify monitoring requirements or expand contraindication language
• additional payer restrictions tighten coverage on any remaining off-label uses
• manufacturing disruptions affect generic supply and create short-term spikes followed by re-stabilization

Directional expectation: revenue contraction in high-restriction geographies and faster margin erosion.

Upside projection

Upside requires one of:

• new guideline updates supporting specific subpopulations or dosing strategies (not driven by broad COVID-19 claims)
• renewed R&D success that changes practice in a focused indication beyond current use patterns
• regional policy harmonization that supports reimbursement for certain off-label settings

Directional expectation: modest volume expansion but still constrained by generic pricing.

---

Where do clinical and market signals intersect for hydroxychloroquine sulfate?

Hydroxychloroquine’s commercial future is governed by evidence-driven utilization rather than by patent-protected innovation. Clinical outcomes already determined the COVID-19 practice shift, and that shift translates into durable volume reallocation.

The key operational implication: new clinical trial spending for hydroxychloroquine sulfate is only rational if it targets a narrower, defensible indication, a new formulation/dosing approach with evidence, or a specific patient subset where guideline language could change.

---

What evidence underpins the current guideline position?

• WHO guidance in mid-2020 moved against hydroxychloroquine for COVID-19 treatment pathways based on randomized trial evidence and safety considerations. (WHO, 2020) [1]
• US NIH Treatment Guidelines reflected non-recommendation for hydroxychloroquine for COVID-19, aligning with evidence from major trials and platform results. (NIH, 2020) [2]
• RECOVERY trial results found no improvement in key outcomes for hospitalized COVID-19 patients receiving hydroxychloroquine. (RECOVERY Collaborative Group, 2020) [3]

These sources define why the market does not treat hydroxychloroquine as a growth engine tied to infectious disease cycles.

---

Key Takeaways

• Hydroxychloroquine sulfate’s post-COVID clinical activity is largely non-registrational and utilization- or safety-focused, following major randomized trial and guideline reversals.
• The market is mature and genericized; revenue growth is constrained by pricing compression and formulary substitution.
• Forward projections should anchor on stable autoimmune baseline demand and treat infectious-disease contribution as structurally diminished.
• Upside depends on narrow, evidence-driven practice change; otherwise the product remains a low-growth, high-competition staple.

---

FAQs

1) Is hydroxychloroquine sulfate still recommended for COVID-19 in major guidelines?

No. WHO and NIH guidance moved away from hydroxychloroquine for COVID-19 treatment, reflecting randomized trial outcomes and risk-benefit assessments. [1], [2]

2) What randomized evidence most influenced the COVID-19 market collapse?

RECOVERY reported no clinical benefit for hospitalized patients receiving hydroxychloroquine, which aligned with the broad guidance shift away from the drug. [3]

3) Does off-label COVID prescribing still exist?

It can persist in limited, non-uniform ways by country and clinician preference, but guideline non-recommendation prevents broad, sustained demand recovery. [1], [2]

4) What drives hydroxychloroquine sales now?

Baseline autoimmune disease utilization and generic access in established therapeutic contexts. COVID-era incremental demand has not returned to peak levels.

5) What would change the commercial outlook materially?

A new, guideline-changing evidence package that supports a specific indication, subpopulation, or dosing strategy with clear clinical benefit, along with payer and regulator alignment.

---

References

[1] World Health Organization. (2020). WHO advises against the use of hydroxychloroquine for COVID-19. World Health Organization.
[2] National Institutes of Health. (2020). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: Hydroxychloroquine.
[3] RECOVERY Collaborative Group. (2020). Hydroxychloroquine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet.